The two objectives of this study were to determine the range of recommended follow-up strategies for patients with lung cancer treated with curative intent and to estimate the cost of such follow-up.
Ten articles delineating eight specific follow-up strategies were identified from a Medline search of the literature for 1980 through 1995.
An economic analysis was done of the costs associated with the identified strategies.
Charge data obtained from the Part B Medicare Annual Data file and the Hospital Outpatient Bill file were used as a proxy for cost.
Follow-up intensity varied widely across strategies for 5 years of posttreatment follow-up.
Medicare-allowed charges for 5-year follow-up ranged from a low of $946 to a high of $5645.
When Medicare-allowed charges were converted to a proxy for actual charges by a conversion ratio of 1.62, the range was $1533 to $9145, a fivefold difference in charges.
There was no indication that more intensive, higher-cost strategies increased survival or quality of life.
The published literature, including textbooks, holds few answers in this area.
Mots-clés Pascal : Carcinome, Bronchopulmonaire, Pneumectomie, Analyse avantage coût, Economie santé, Evaluation, Tomodensitométrie, Imagerie RMN, Bronchoscopie, Etude longitudinale, Traitement, Exploration, Homme, Etats Unis, Amérique du Nord, Amérique, Appareil respiratoire pathologie, Poumon pathologie, Bronche pathologie, Tumeur maligne, Chirurgie, Radiodiagnostic, Endoscopie
Mots-clés Pascal anglais : Carcinoma, Bronchopulmonary, Pneumectomy, Cost benefit analysis, Health economy, Evaluation, Computerized axial tomography, Nuclear magnetic resonance imaging, Bronchoscopy, Follow up study, Treatment, Exploration, Human, United States, North America, America, Respiratory disease, Lung disease, Bronchus disease, Malignant tumor, Surgery, Radiodiagnosis, Endoscopy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0422810
Code Inist : 002B11A. Création : 10/04/1997.